The latest call
FetchingSeaStar Medical Holding Corporation reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
$0.82-21.5%Nov 13 close
The latest quarter (ended September 30, 2026) is from SeaStar Medical’s earnings press release of November 12, 2026. It will be replaced by the official quarterly report (10-Q) once SeaStar Medical files it.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $635K | $183K | +246.99% |
| Profit | -$4.5M | -$3.5M | -30.44% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The strength of the QUELIMMUNE therapy adoption in this ultra-rare pediatric AKI market provides great promise for our pipeline indications,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device – a randomIZEd clinical trial in AKI) pivotal trial is evaluating the safety and efficacy of the SCD therapy in 339 adults with AKI in the ICU receiving CRRT. The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with the SCD therapy in addition to CRRT as the standard of care, compared with the control group receiving only CRRT standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of the SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome.
The company’s own description, as it appears at the foot of the release.
The quote, the company description and the latest quarter come from SeaStar Medical’s earnings press release (an Item 2.02 8-K) filed November 12, 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Read the release on EDGAR Share prices are split- and dividend-adjusted.
SeaStar Medical Holding Corporation reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Just reported
From SeaStar Medical Holding Corporation's results release of November 12, 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Actual
$635K
+247% y/y
+3.3% q/q
Guided
—
No guide given
Actual
-$4.6M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.